On August 2, 2021, Zentera Therapeutics, a clinical-stage biopharmaceutical company, announced the completion of a $75 million Series B financing. Founding investors OrbiMed Advisors Asia and Tybourne Capital Management led the financing. Wilson Sonsini Goodrich & Rosati advised Tybourne Capital in the transaction.

Shanghai, China-based Zentera Therapeutics was formed by Zentalis Pharmaceuticals Inc. to develop cancer therapies in China. Zentera plans to use the proceeds of the financing to advance the clinical development of three of Zentalis’ product candidates, and to expand its pipeline through additional business development opportunities for China and global development.

The Wilson Sonsini team advising Tybourne Capital Management includes partner Dan Koeppen and associate Meghan Burton.

For more information, please see Zentera Therapeutics’ press release.